{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:14:50Z","timestamp":1788516890937,"version":"build-2803163510"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Oncofetal antigens are emerging targets for chimeric antigen receptor (CAR)-based immunotherapies due to their developmentally restricted expression and frequent re-emergence in malignant cells. These antigens are tightly linked to cellular plasticity, stem-like programs, immune evasion, and resistance to cytotoxic therapies, making them biologically compelling targets. Multiple oncofetal antigens have entered early-phase clinical trials as CAR-T cell targets with promising results in several cancers including neuroblastoma and diffuse midline gliomas. However, antitumor efficacy in most solid malignancies has thus far been modest. This reflects shared obstacles, including low-level expression in normal tissues, intratumoral antigen heterogeneity, immune suppression within the tumor microenvironment, CAR-T cell exhaustion, and limited persistence. In this Mini-Review, we discuss the biological foundations of oncofetal antigen expression, synthesize clinical and pre-clinical experience targeting these antigens with CAR-T cell therapies, and highlight emerging engineering and combination strategies designed to overcome current limitations. We propose that integrating principles from developmental biology, tumor evolution, and immuno-engineering will be essential to unlocking the therapeutic potential of oncofetal antigen-directed CAR-T therapies in solid tumors.<\/jats:p>","DOI":"10.3389\/fcell.2026.1910208","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:36:55Z","timestamp":1788514615000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challenges"],"prefix":"10.3389","volume":"14","author":[{"given":"Sam Sebastian","family":"Smith","sequence":"first","affiliation":[{"name":"Royal Marsden Hospital","place":["London, United Kingdom"]},{"name":"The Institute of Cancer Research","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astero","family":"Klampatsa","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s004270100140","article-title":"Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development","volume":"211","author":"Al-Shawi","year":"2001","journal-title":"Dev. Genes Evol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 protein expression in human cancer and normal tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin. Cancer Research An Official Journal Am. Assoc. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s13238-014-0059-7","article-title":"ROR1, an embryonic protein with an emerging role in cancer biology","volume":"5","author":"Borcherding","year":"2014","journal-title":"Protein and Cell."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1002\/mco2.427","article-title":"Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy","volume":"4","author":"Cao","year":"2023","journal-title":"MedComm"},{"key":"B7","doi-asserted-by":"publisher","first-page":"15870","DOI":"10.1038\/s41598-024-66838-9","article-title":"Pan-cancer analysis and the oncogenic role of glypican 1 in hepatocellular carcinoma","volume":"14","author":"Cao","year":"2024","journal-title":"Sci. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"qiae144","DOI":"10.1093\/jleuko\/qiae144","article-title":"Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma","volume":"117","author":"Cao","year":"2025","journal-title":"J. Leukocyte Biology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"857308","DOI":"10.3389\/fimmu.2022.857308","article-title":"GPC2 is a potential diagnostic, immunological, and prognostic biomarker in pan-cancer","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharmthera.2015.01.010","article-title":"Ror2 as a therapeutic target in cancer","volume":"150","author":"Debebe","year":"2015","journal-title":"Pharmacol. and Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"102353","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"102175","DOI":"10.1016\/j.eclinm.2023.102175","article-title":"RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial","volume":"63","author":"Fu","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B15","first-page":"5603","article-title":"Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro","volume":"62","author":"Fukuda","year":"2002","journal-title":"Cancer Research"},{"key":"B16","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s43018-026-01124-3","article-title":"Hypoxia-responsive CEA-Targeted CAR T cells in CEA-Positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial","volume":"7","author":"Gao","year":"2026","journal-title":"Nat. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e008659","DOI":"10.1136\/jitc-2023-008659","article-title":"Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers","volume":"12","author":"Gargett","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.3390\/cancers13194841","article-title":"High prevalence of 5T4\/Trophoblast glycoprotein in soft tissue sarcomas","volume":"13","author":"Groothuis","year":"2021","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","first-page":"101741","DOI":"10.1016\/j.bbrep.2024.101741","article-title":"GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma","volume":"39","author":"Guan","year":"2024","journal-title":"Biochem. Biophysics Reports"},{"key":"B20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/mco2.34","article-title":"Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo","volume":"1","author":"Guo","year":"2020","journal-title":"MedComm"},{"key":"B21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/BTT.S291768","article-title":"Armored CAR T-Cells: the next chapter in T-Cell cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biol. Targets Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J. Immunotherapy Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","article-title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","volume":"40","author":"Heitzeneder","year":"2022","journal-title":"Cancer Cell."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","article-title":"Anti-extra domain B splice variant of fibronectin antibody-drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint blockade","volume":"21","author":"Hooper","year":"2022","journal-title":"Mol. Cancer Therapeutics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1038\/s41467-026-69796-0","article-title":"NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors","volume":"17","author":"Humer","year":"2026","journal-title":"Nat. Commun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","article-title":"Phase I study of ROR1-Specific CAR-T cells in advanced hematopoietic and epithelial malignancies","volume":"31","author":"Jaeger-Ruckstuhl","year":"2025","journal-title":"Clin. Cancer Research An Official Journal Am. Assoc. Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.3390\/cancers16234052","article-title":"Carcinoembryonic antigen expression in human tumors: a tissue microarray study on 13,725 tumors","volume":"16","author":"Jansen","year":"2024","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1749-8104-4-33","article-title":"Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis","volume":"4","author":"Jen","year":"2009","journal-title":"Neural Dev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00018-010-0292-z","article-title":"GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells","volume":"67","author":"Jin","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e49392","DOI":"10.7554\/eLife.49392","article-title":"GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab","volume":"9","author":"Kato","year":"2020","journal-title":"eLife"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor\u2013modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41417-019-0104-z","article-title":"HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases","volume":"27","author":"Katz","year":"2020","journal-title":"Cancer Gene Therapy."},{"key":"B33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/2767-9764.CRC-25-0399","article-title":"CLDN6 expression plasticity in ovarian cancer: insights into therapeutic optimization for CLDN6-Targeted immunotherapy","volume":"6","author":"Kimura","year":"2026","journal-title":"Cancer Res. Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3892\/ijo.3.5.909","article-title":"GANGLIOSIDE GD(2) EXPRESSION IN THE HUMAN NERVOUS-SYSTEM AND IN NEUROBLASTOMAS - AN IMMUNOHISTOCHEMICAL STUDY","volume":"3","author":"Lammie","year":"1993","journal-title":"Int. J. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jri.2010.10.001","article-title":"Tumor-associated glycoprotein (TAG-72) is a natural ligand for the C-type lectin-like domain that induces anti-inflammatory orientation of early pregnancy decidual CD1a+ dendritic cells","volume":"88","author":"Laskarin","year":"2011","journal-title":"J. Reproductive Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.7150\/ijbs.88539","article-title":"NK-92MI cells engineered with Anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer","volume":"20","author":"Li","year":"2024","journal-title":"Int. Journal Biological Sciences"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","volume":"31","author":"Li","year":"","journal-title":"Nat. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40364-025-00730-0","article-title":"ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2","volume":"13","author":"Li","year":"","journal-title":"Biomark. Research"},{"key":"B40","doi-asserted-by":"publisher","first-page":"107277","DOI":"10.1016\/j.isci.2023.107277","article-title":"Emerging biomedical imaging-based companion diagnostics for precision medicine","volume":"26","author":"Liao","year":"2023","journal-title":"iScience"},{"key":"B41","doi-asserted-by":"publisher","first-page":"117252","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomed. and Pharmacother."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1101\/2025.09.22.677496","article-title":"Potentiating CAR-T bystander killing by enhanced Fas\/FasL signaling mitigates antigen escape in heterogeneous tumors","author":"Lin","year":"2025"},{"key":"B43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13046-016-0396-x","article-title":"DNA methylation of claudin-6 promotes breast cancer cell migration and invasion by recruiting MeCP2 and deacetylating H3Ac and H4Ac","volume":"35","author":"Liu","year":"2016","journal-title":"J. Exp. and Clin. Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","volume":"31","author":"Locatelli","year":"2025","journal-title":"Nat. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"key":"B46","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1249929","DOI":"10.3389\/fphar.2023.1249929","article-title":"Biology of GD2 ganglioside: implications for cancer immunotherapy","volume":"14","author":"Machy","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Medicine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"B50","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41586-024-08150-0","article-title":"Progressive plasticity during colorectal cancer metastasis","volume":"637","author":"Moorman","year":"2025","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejmp.2020.06.024","article-title":"Increased carcinoembryonic antigen expression on the surface of lung cancer cells using gold nanoparticles during radiotherapy","volume":"76","author":"Mueller","year":"2020","journal-title":"Phys. Medica"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/ijtm6010006","article-title":"Oncofetal reprogramming: a new frontier in cancer therapy resistance","volume":"6","author":"Nguyen","year":"2026","journal-title":"Int. J. Transl. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"201067","DOI":"10.1016\/j.omton.2025.201067","article-title":"GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts","volume":"33","author":"Okada","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"114444","DOI":"10.1016\/j.expneurol.2023.114444","article-title":"Glypican-2 defines age-dependent axonal response to chondroitin sulfate","volume":"366","author":"Ouchida","year":"2023","journal-title":"Exp. Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/CJI.0000000000000203","article-title":"Preclinical assessment of CAR T-Cell therapy targeting the tumor antigen 5T4 in ovarian cancer","volume":"41","author":"Owens","year":"2018","journal-title":"J. Immunotherapy Hagerst. Md"},{"key":"B58","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/cells14100726","article-title":"Unraveling Glypican-3: from structural to pathophysiological roles and mechanisms\u2014an integrative perspective","volume":"14","author":"Piao","year":"2025","journal-title":"Cells"},{"key":"B59","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-9966-27-5","article-title":"Combined effects of 5-Fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human Colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy","volume":"27","author":"Prete","year":"2008","journal-title":"J. Exp. and Clin. Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"813832","DOI":"10.3389\/fimmu.2021.813832","article-title":"CAR-T plus radiotherapy: a promising combination for immunosuppressive tumors","volume":"12","author":"Qin","year":"2022","journal-title":"Front. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"B62","doi-asserted-by":"publisher","first-page":"eabm0306","DOI":"10.1126\/scitranslmed.abm0306","article-title":"A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo","volume":"14","author":"Sandberg","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/cancers17060920","article-title":"The chimeric antigen receptor T cell target claudin 6 is a marker for early organ-specific epithelial progenitors and is expressed in some pediatric solid tumor entities","volume":"17","author":"Seidmann","year":"2025","journal-title":"Cancers"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1038\/s41467-024-47649-y","article-title":"Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression","volume":"15","author":"Shaw","year":"2024","journal-title":"Nat. Communications"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen Receptor-Glypican-3 T-Cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.omto.2023.04.003","article-title":"Durable remission related to CAR-T persistence in R\/R B-ALL and long-term persistence potential of prime CAR-T","volume":"29","author":"Shiqi","year":"2023","journal-title":"Mol. Therapy Oncolytics"},{"key":"B67","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.omto.2021.01.002","article-title":"Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer","volume":"20","author":"Shu","year":"2021","journal-title":"Mol. Therapy Oncolytics"},{"key":"B68","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/protein\/gzl033","article-title":"Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo","volume":"19","author":"Silacci","year":"2006","journal-title":"Protein Eng. Des. Sel."},{"key":"B69","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/bjc.1990.20","article-title":"Immunohistological distribution of 5T4 antigen in normal and malignant tissues","volume":"61","author":"Southall","year":"1990","journal-title":"Br. Journal Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00262-016-1917-3","article-title":"5T4 oncofoetal antigen: an attractive target for immune intervention in cancer","volume":"66","author":"Stern","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e75106","DOI":"10.1371\/journal.pone.0075106","article-title":"The tight-junction protein claudin-6 induces epithelial differentiation from mouse F9 and embryonic stem cells","volume":"8","author":"Sugimoto","year":"2013","journal-title":"PloS One"},{"key":"B74","doi-asserted-by":"publisher","first-page":"100986","DOI":"10.1016\/j.medj.2025.100986","article-title":"Advances and perspectives in CEA-Targeted therapies: from classic biomarker toward actionable therapeutic target","volume":"7","author":"Sun","year":"2026","journal-title":"Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1080\/08820139.2023.2264332","article-title":"CAR-T therapy targets Extra domain B of fibronectin positive solid tumor cells","volume":"52","author":"Tang","year":"2023","journal-title":"Immunol. Investigations"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-Specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunology, Immunotherapy CII."},{"key":"B77","first-page":"3118","article-title":"Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3","volume":"46","author":"Thor","year":"1986","journal-title":"Cancer Research"},{"key":"B78","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/2326-6066.CIR-20-0280","article-title":"Antitumor effects of CAR T cells redirected to the EDB splice variant of fibronectin","volume":"9","author":"Wagner","year":"2021","journal-title":"Cancer Immunology Research"},{"key":"B79","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fonc.2019.00614","article-title":"The expression, regulation, and biomarker potential of Glypican-1 in cancer","volume":"9","author":"Wang","year":"2019","journal-title":"Front. Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ymthe.2022.12.009","article-title":"Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1554312","DOI":"10.3389\/fcell.2025.1554312","article-title":"The role of tenascin-C in tumor microenvironments and its potential as a therapeutic target","volume":"13","author":"Wang","year":"2025","journal-title":"Front. Cell Developmental Biology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"102400","DOI":"10.1016\/j.xcrm.2025.102400","article-title":"ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice","volume":"6","author":"Weber","year":"2025","journal-title":"Cell Rep. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e009743","DOI":"10.1136\/jitc-2024-009743","article-title":"IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors","volume":"12","author":"Wickman","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"45244","DOI":"10.31083\/FBL45244","article-title":"Therapeutic potential of CLDN family proteins in ovarian cancer: emerging biomarkers and targets","volume":"30","author":"Wu","year":"2025","journal-title":"Front. Bioscience (Landmark Edition)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"a006957","DOI":"10.1101\/cshperspect.a006957","article-title":"T-Cell tolerance: central and peripheral","volume":"4","author":"Xing","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1643941","DOI":"10.3389\/fimmu.2025.1643941","article-title":"Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Therapy The Journal Am. Soc. Gene Ther."},{"key":"B88","first-page":"99","article-title":"5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors","volume":"4","author":"Zhao","year":"2007","journal-title":"Cell. and Molecular Immunology"},{"key":"B89","doi-asserted-by":"publisher","first-page":"824208","DOI":"10.3389\/fonc.2022.824208","article-title":"Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma","volume":"12","author":"Zheng","year":"2022","journal-title":"Front. Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2025.13525","article-title":"Exploring the mechanism of fibronectin Extra domain B in the tumor microenvironment and implications for targeted immunotherapy and diagnostics","volume":"31","author":"Zhou","year":"2025","journal-title":"Mol. Med. Rep."},{"key":"B91","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-026-02780-8","article-title":"Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells","volume":"11","author":"Zi","year":"2026","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1910208\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:36:57Z","timestamp":1788514617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1910208\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":91,"alternative-id":["10.3389\/fcell.2026.1910208"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1910208","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1910208"}}